Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma

Oncotarget

Volumn 8, Issue 14, 2017, Pages 22370-22384

  Tsigelny, Igor F ^a,b,c   Mukthavaram, Rajesh ^c   Kouznetsova, Valentina L ^b,c   Chao, Ying ^c   Babic, Ivan ^c   Nurmemmedov, Elmar ^d   Pastorino, Sandra ^c   Jiang, Pengfei ^c   Calligaris, David ^e   Agar, Nathalie ^e   Scadeng, Miriam ^f   Pingle, Sandeep C ^c   Wrasidlo, Wolfgang ^a,c   Makale, Milan T ^c   Kesari, Santosh ^a,c,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

In silico rational drug design; Inhibitor scaffold; OLIG2; Pharmacophore; Transcription factors

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 [4 [(1 ETHYL 3 PIPERIDYL)AMINO] 6 METHYL 2 PYRIMIDINYL]GUANIDINE; 2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; ANTINEOPLASTIC AGENT; CD133 ANTIGEN; MESSENGER RNA; MYELIN BASIC PROTEIN; NESTIN; NEUROGENIC DIFFERENTIATION FACTOR; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN P21; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN 1; SHORT HAIRPIN RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR E2A; UNCLASSIFIED DRUG; 1-(3,4-DICHLOROPHENYL)-3-(4-((1-ETHYL-3-PIPERIDYL)AMINO)-6-METHYL-2-PYRIMIDINYL)GUANIDINE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; GUANIDINE DERIVATIVE; MOLECULAR LIBRARY; NERVE PROTEIN; OLIG2 PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; DIMERIZATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOPHORE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL GROWTH; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; GENETICS; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PROTEIN CONFORMATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL SURVIVAL; COMPUTER SIMULATION; DRUG DESIGN; GLIOBLASTOMA; GUANIDINES; HUMANS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; SMALL MOLECULE LIBRARIES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016945251     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5633     Document Type: Article

References (47)

1. Pabo CO and Sauer RT. Transcription factors: structural families and principles of DNA recognition. Annu Rev Biochem 1992; 61: 1053-1095.
2. Riley T, Sontag E, Chen P, and Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
3. Nebert DW. Transcription factors and cancer: an overview. Toxicology 2002; 181-182: 131-141.
4. Papavassiliou AG. Transcription factors: structure, function, and implication in malignant growth. Anticancer Res 1995; 15: 891-894.
5. Tsigelny IF, Kouznetsova VL, Baitaluk M, and Changeux JP. A hierarchical coherent-gene-group model for brain development. 2013; Genes, brain, and behavior 12: 147-165.
6. Atkinson GP, Nozell SE, and Benveniste ET. NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010; 10: 575-586.
7. Darnell JE, Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740-749.
8. Karamouzis MV, Gorgoulis VG, and Papavassiliou AG. Transcription factors and neoplasia: vistas in novel drug design. Clin Cancer Res 2002; 8: 949-961.
9. Liu Y, Li C, and Lin J. STAT3 as a Therapeutic Target for Glioblastoma. Anticancer Agents Med Chem 2010; 10: 512-519.
10. Arkin MR and Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3: 301-317.
11. Tsigelny IF, Kouznetsova VL, Pingle SC and Kesari S. bHLHTranscription Factors Inhibitors For Cancer Therapy: General Features For InSilico Drug Design. Current medicinal chemistry (2014).
12. Berg T. Inhibition of transcription factors with small organic molecules. Curr Opin Chem Biol 2008; 12: 464-471.
13. Rishi V, Potter T, Laudeman J, Reinhart R, Silvers T, Selby M, Stevenson T, Krosky P, Stephen AG, Acharya A, Moll J, Oh WJ, Scudiero D, Shoemaker RH,Vinson C. A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. Anal Biochem 2005; 340: 259-271.
14. Lu X, Vogt PK, Boger DL and Lunec J. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep 2008; 19: 825-830.
15. Xu Y, Shi J, Yamamoto N, Moss JA, Vogt PK, Janda KD. A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem 2006; 14: 2660-2673.
16. Lao BB, Grishagin I, Mesallati H, Brewer TF, Olenyuk BZ, Arora PS. In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl AcadSci U S A 2014; 111: 7531-7536.
17. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
18. Cheng L, Bao S and Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010; 80: 654-665.
19. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell stem cell 2009; 5: 504-514.
20. Clackson T and Wells, JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995; 267: 383-386 (1995).
21. Jubb H, Higueruelo AP, Winter A, and Blundell TL. Structural biology and drug discovery for protein-protein interactions. Trends in pharmacological sciences 2012; 33: 241-248.
22. Kouznetsova VL, Tsigelny IF, Nagle MA and Nigam SK. Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1). Bioorg Med Chem 2011; 19: 3320-3340.
23. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF and Nigam SK. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). Journal of proteome research 2011; 10: 2842-2851.
24. Tsigelny IF, Kouznetsova VL, Biswas N, Mahata SK and O'Connor DT. Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: virtual screening and functional testing identify novel small molecule therapeutics of hypertension. Bioorg Med Chem 2013; 21: 5855-5869.
25. Dietrich J, Imitola J and Kesari S. Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol 2008; 5: 393-404.
26. Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004; 63: 499-509.
27. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007; 53: 503-517.
28. Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011; 19: 359-371.
29. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, Verma IM. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 2011; 108: 4274-4280.
30. Wen PY and Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
31. Ellenberger T, Fass D, Arnaud, M and Harrison SC. Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer. Genes Dev 1994; 8: 970-980.
32. Longo A, Guanga GP and Rose RB. Crystal structure of E47-NeuroD1/beta2 bHLH domain-DNA complex: heterodimer selectivity and DNA recognition. Biochemistry 2008; 47: 218-229.
33. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1: 269-277.
34. Fischer PM. Protein-Protein Interactions in Drug Discovery Drug Design Reviews 2005; 2: 179-207.
35. Prieto C and De Las Rivas J. APID: Agile Protein Interaction DataAnalyzer. Nucleic Acids Res 2006; 34: W298-302.
36. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 23: 2947-2948.
37. Oliveros JC. VENNY. An interactive tool for comparing lists with Venn Diagrams. (2007).
38. Jarvis, R. A. & Patrick, E. A. Clustering Using a Similarity Measure Based on Shared near Neighbors. Ieee T Comput 2007; C-22: 1025-1034.
39. Williams C. Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance. Mol Divers 2006; 10: 311-332.
40. Thorner DA, Willett P, Wright PM and Taylor R. Similarity searching in files of three-dimensional chemical structures: representation and searching of molecular electrostatic potentials using field-graphs. J Comput Aided Mol Des 1997; 11: 163-174.
41. Willett P. Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance. J chem inf comput sci 1998; 38: 983-996.
42. Rajesh M, Sen J, Srujan M, Mukherjee K, Sreedhar B, Chaudhuri A. Dramatic influence of the orientation of linker between hydrophilic and hydrophobic lipid moiety in liposomal gene delivery. J Am Chem Soc 2007; 129: 11408-11420.
43. Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 2010; 12: 1205-1219.
44. Lo MC, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 2004; 332: 153-159.
45. Institute of Laboratory Animal Resources. Guide for the care and Use of Laboratory Animals. National Academy Press: Washington, DC (1996).
46. Office of Laboratory Animal Welfare. Public Health services Policy on Human Care and Use of Laboratory Animals. (2002) http://grants/olaw/references/phspol.htm.
47. US Office of Sciences and Technology Policy. (1985) Laboratory Animal Welfare: U.S government principles for the utilization and care of vertabrate animals used in testing, research and training. Fed Regist 1985; 50: 20864-20865.